Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07602855 |
| Title | A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) |
| Acronym | EMBOLD PanTumour-103 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | GlaxoSmithKline |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| GSK Investigational Site | RECRUITING | Los Angeles | California | 90027 | United States | Details |
| GSK Investigational Site | RECRUITING | Wilson | North Carolina | 27893-3484 | United States | Details |
| GSK Investigational Site | RECRUITING | Canton | Ohio | 44718 | United States | Details |
| GSK Investigational Site | RECRUITING | Osaka | 573-1191 | Japan | Details |